We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 617

A summary of major developments in key areas - general counsel update - July 2014
  • Herbert Smith Freehills LLP
  • Australia, European Union, Hong Kong, United Kingdom
  • July 15 2014

Legislation, in the form of a Regulation and Directive, has been published in the Official Journal of the European Union which will substantially

Regulating the nip and tuck: cosmetic medical services growth expands
  • Maddocks
  • Australia
  • May 21 2015

Cosmetic medicine is one of Australia's fastest growing consumer markets, yet the AUD $1 billion1 consumer market is largely unregulated. On the

ACCC v Pfizer some guidance to pharmaceutical companies on navigating competition risk
  • Herbert Smith Freehills LLP
  • Australia
  • March 3 2015

In brief The Federal Court of Australia has recently dismissed the ACCC’s case against pharmaceutical company Pfizer. The ACCC alleged that Pfizer had

ACCC pursues Pfizer over Lipitor drug
  • HopgoodGanim
  • Australia
  • September 2 2014

Click here to view the video

Australian Federal Court decides protecting your brand against generic pharmaceuticals is not a misuse of market power
  • Bird & Bird
  • Australia
  • March 18 2015

In a decision which will be welcomed by many pharmaceutical companies the Federal Court of Australia recently dismissed proceedings instituted by the

Hospital’s by-laws flatline on the competition table
  • King & Wood Mallesons
  • Australia
  • December 22 2014

The ACCC has launched proceedings in the Federal Court against Little Company of Mary Health Ltd and its subsidiary Calvary Health Care Riverina Ltd

Below cost pricing?
  • King & Wood Mallesons
  • Australia
  • September 1 2014

According to reports in Friday's Australian FianancialRreview, (Hannah Low, page 32), the ACCC has sought to widen its claim against Pfizer. We

Competition law scrutiny of patent settlements - a new focus in Australia?
  • DLA Piper LLP
  • Australia
  • November 15 2016

Settlement agreements in patent disputes between pharmaceutical companies may soon face greater competition law scrutiny in Australia. The

Misuse of market power: How proposed changes to the law will affect the private health insurance sector
  • DLA Piper LLP
  • Australia
  • April 6 2016

The Turnbull Government recently announced that it will adopt the Harper Review's recommendation to amend section 46 of the Competition and Consumer

Harper Review - implications for the private health insurance industry
  • DLA Piper LLP
  • Australia
  • April 10 2015

On 31 March 2015 the final report of the Competition Policy Review Panel chaired by Professor Ian Harper (Harper Review) was released. The Harper